TLR4 and neoplasm: However, recent findings have shown that the ability of CIRP to function as a TLR4 ligand can also induce an antitumorigenic inflammatory response in mice with E.G7-OVA tumors, showing that this aspect of CIRP function can potentially be applied clinically to drive a tumor rejection response [82].